#United Kingdom #AI Technology #Belfast #PulseAI #ECG Diagnostics

PulseAI Secures Seed Funding to Enhance AI-Driven ECG Technology

In a pivotal development for cardiac health diagnostics, PulseAI, a rapidly growing player in the realm of AI-enhanced cardiac diagnostics, has recently concluded its seed funding round. This funding was primarily led by Innovation Ulster Limited, with notable participation from two influential entities in the health tech sector—The Mortara Group and The Francis Crick Institute. This financial boost is set to propel PulseAI's AI-ECG technology further, paving the path for regulatory approvals, particularly from the US FDA under its 510(k) program.

Globally, more than 300 million electrocardiograms (ECGs) are conducted every year, emphasizing the crucial role of ECGs in detecting heart conditions. Despite its significance, the interpretation of ECGs often relies heavily on the expertise of trained specialists, which can introduce delays, variability in diagnosis, and instances of missed opportunities for timely interventions. PulseAI aims to tackle these challenges by providing clinical decision support that is both efficient and accurate across various healthcare settings, including primary care and emergency response.

To strengthen its leadership and innovation strategy, Dr. Justin Mortara has joined PulseAI as the Chair of the Board. Dr. Mortara is recognized for his significant contributions to ECG technology while previously serving as the CEO of Mortara Instruments. His expertise and vision are expected to align PulseAI more closely with leaders in cardiac diagnostics and monitoring systems, facilitating the transition from innovation to market-ready solutions.

The core of PulseAI's technology involves machine learning models that have been trained on extensive ECG data from renowned institutions throughout Europe and the United States. This AI-driven approach seeks to improve diagnostic accuracy and speed, greatly benefiting both patients and healthcare providers alike.

With this new financial backing, PulseAI plans to focus on several key areas of advancement:

• - Regulatory Progress: Accelerating its pathway to attain FDA 510(k) clearance, which is crucial for the commercial utilization of medical devices in the United States.
• - Clinical Validation: Expanding the clinical validation of its technology across diverse populations and various care settings to ensure reliability and effectiveness.
• - Product Development: Enhancing the product for enterprise and Original Equipment Manufacturer (OEM) integration, making it viable for wider adoption in hospitals and clinics.
• - Partnership Expansion: Increasing collaborations with device manufacturers and healthcare networks to broaden the reach and availability of its AI-ECG platform.

Dr. Alan Kennedy, the Founder and CEO of PulseAI, expressed excitement about this investment, indicating it as a significant milestone for the company. “Our goal is to deliver advanced ECG technology that not only expedites but also enhances the accuracy of cardiac diagnostics. We aim to reduce variability and enhance access to high-quality diagnostics across the healthcare spectrum,” he remarked.

Incoming Chair Justin Mortara echoed this sentiment, emphasizing PulseAI's unique position at the convergence of clinical rigor and scalable technology to meet pressing market needs. He believes that PulseAI's innovative approach can bridge the gap between traditional medical devices and a wide array of emerging consumer wearables, thus transforming ECG interpretation and enhancing overall healthcare delivery.

In conclusion, PulseAI stands on the brink of a significant transformation in cardiac diagnostics. Through strategic funding and leadership, it is poised to harness the power of AI to streamline cardiac health assessments, ultimately improving diagnostic outcomes for patients and assuring timely medical interventions across healthcare landscapes.


This investment solidifies PulseAI’s commitment to revolutionizing ECG diagnostics, making it more accessible, faster, and reliable as healthcare continues to evolve.